Amphastar Pharmaceuticals (AMPH) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Amphastar Pharmaceuticals (AMPH) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 933.33 Mn | 643.20 Mn | 93.47 Mn | 4.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.72% |
| Mar 31, 2026 | -37.91% |
| Dec 31, 2025 | 11.89% |
| Sep 30, 2025 | 2.66% |
| Jun 30, 2025 | 20.81% |
| Mar 31, 2025 | 0.44% |
| Dec 31, 2024 | 23.88% |
| Sep 30, 2024 | 9.30% |
| Jun 30, 2024 | 63.88% |
| Mar 31, 2024 | 122.74% |
| Dec 31, 2023 | -192.70% |
| Sep 30, 2023 | 117.93% |
| Jun 30, 2023 | 173.65% |
| Mar 31, 2023 | 96.68% |
| Dec 31, 2022 | 24.46% |
| Sep 30, 2022 | 153.54% |
| Jun 30, 2022 | -27.88% |
| Mar 31, 2022 | 138.61% |
| Dec 31, 2021 | 126.52% |
| Sep 30, 2021 | 167.58% |